100th Day Of Lockdown

Maharashtra180298931548053 Tamil Nadu94049529261264 Delhi89802599922803 Gujarat33318240381869 Uttar Pradesh2405616629718 West Bengal1917012528683 Rajasthan1831214574421 Telangana173578082267 Karnataka165148065253 Andhra Pradesh152526988193 Haryana1494110499240 Madhya Pradesh1386110655581 Bihar10204781173 Assam8956583212 Jammu and Kashmir76954856105 Odisha7316535333 Punjab56683989149 Kerala4594243626 Uttarakhand2791190937 Chhatisgarh2339193713 Jharkhand2339160512 Tripura140110931 Manipur12605790 Goa11984783 Himachal Pradesh9796179 Puducherry73930112 Nagaland5351820 Chandigarh4463676 Arunachal Pradesh182601 Mizoram1601230 Sikkim88490 Meghalaya50421
Nation Other News 23 Jun 2020 Patanjali drug can c ...

Patanjali drug can cure COVID-19, claims Ramdev; Really? asks Ayush Ministry

Published Jun 23, 2020, 8:57 pm IST
Updated Jun 23, 2020, 8:57 pm IST
Ayush Ministry sought from the company detailed report on composition, testing and other data of the drugs
Yoga guru Ramdev addresses the media during the launch of 'Coronil' and 'Swasari', ayurvedic medicines claimed by Patanjali to cure coronavirus disease, in Haridwar. PTI photo
 Yoga guru Ramdev addresses the media during the launch of 'Coronil' and 'Swasari', ayurvedic medicines claimed by Patanjali to cure coronavirus disease, in Haridwar. PTI photo

Haridwar/New Delhi: Yoga guru Ramdev's herbal medicine company Patanjali Ayurved on Tuesday claimed to have discovered a medicine that could cure coronavirus in just seven days - a claim that the Ayush Ministry scoffed at by seeking stopping of advertisements for the drug.

While Ramdev claimed that Ayurved-based 'Coronil and Swasari' medicine have shown 100 per cent favourable results during clinical trials on COVID-19 infected patients except those on a life support system, the Ayush Ministry sought from the company detailed report on composition, testing and other data of the drugs.


The ministry also used powers under a 1954 law to ask the firm to "stop advertising/publicizing" claims of corona cure drug until the issue is examined by it.

A government notification bars companies from advertising a cure without government approval. But it wasn't immediately clear if the drug can still be sold.

Talking to PTI, Ramdev said the medicines have been developed by Patanjali Research Center, Haridwar and privately-owned National Institute of Medical Science, Jaipur following all protocols with clinically controlled trial-based evidence.

"Patanjali first conducted clinical case study and conducted clinical control trials following all protocols of drug discovery," he said.

Sidestepping questions on the drug being approved by government agencies such as ICMR, Ramdev said clinical controlled study of these medicines was done in several cities including Delhi, Ahmedabad and Meerut and the RCT (Randomized Clinical Trial) controlled with placebo was conducted at Jaipur-based National Institute of Medical Sciences & Research.

"This was done after getting approval from Clinical Trial Registry of India (CTRI) and all other required formalities," he said. "We have followed all the parameters set up by modern science for such clinical trials."

Reacting to the announcement, the Ministry of Ayush issued a statement saying, "Facts of the claim and details of the stated scientific study are not known" to it.

"Patanjali Ayurved Ltd has been asked to provide at the earliest details of the name and composition of the medicines being claimed for COVID treatment; site(s)/hospital(s), where the research study was conducted for COVID-19; protocol, sample size, Institutional Ethics Committee clearance, CTRI registration and results data of the study (ies) and stop advertising/publicizing such claims till the issue is duly examined," the ministry statement said.

The ministry also asked the concerned State Licensing Authority of Uttarakhand Government to provide copies of license and product approval details of the Ayurvedic medicines being claimed for the treatment of COVID -19.

Under the ministry's guidelines for drug development of ayurvedic formulations, state licensing authority grants licenses for manufacturing any Ayurvedic, Siddha or Unani medicine.

Ramdev at a launch press conference in Haridwar, where his company is based, claimed that his ayurvedic drugs have shown 100 per cent favourable results during the clinical trial.

"We conducted a clinical case study and clinical controlled trial, and found 69 per cent patients recovered in 3 days and 100 patients recovered in 7 days," he said.

According to him, this medicine is useful for prevention from COVID-19 and also for treatment.

Claiming that during the trial other complications of patients were also cured and their critical parameters were normalised, he said no infected patient lost his life during the trial.

Patanjali, he said, had started to work on corona medicines in December 2019.

The Corona kit, priced at Rs 545, would be available pan India within a week. The kit will have medicines for 30 days.

Ramdev said the medicines can be ordered online through a mobile app from next Monday.

The COVID-19 therapy suggested by Patanjali is applicable for adults ranging between 15-80 years of age whereas children are advised to take half the dosage prescribed for adults.

Patanjali's anti-COVID tablet, Divya Coronil Tablet consists of Giloy, Tulsi and Ashwagandha and is prescribed to be taken thrice a day with hot water 30 minutes after breakfast, lunch and dinner.

Medical experts, however, were not convinced by the claims.

Dr Ravi Shekhar Jha, Head of the department and senior consultant, Pulmonology, Fortis Escorts Hospital, Faridabad, said physiologically it is quite impossible that there is any medicine which can finish the viral load from the body in 5-7 days.

"These claims can be very harmful because people, instead of taking actual medical help, may start rushing to these kinds of claims which have no proven clinical trial," he told PTI.

Instead of taking actual medical help, opting for a "desi nuskha" kind of a thing is just going to result in loss of precious time in curing the disease, Jha said.

Noted city-based lung surgeon Dr Arvind Kumar said only a proper clinical trial can prove the efficacy of the medicine.

Haridwar-based Patanjali group has an estimated turnover of around Rs 10,500 crore. It had acquired debt-ridden Ruchi Soya in a corporate insolvency resolution process for around Rs 4,350 crore after competing with Adani Group.

The group is also known for venturing in uncharted areas as it had in August 2018 launched a messaging app 'Kimbho', which could not take off and is now defunct.

Location: India, Uttarakhand, Haridwar